Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have atopic dermatitis (AD) for at least 1 year (365 days) prior to the first administration of study intervention as determined by the investigator through participant interview and/or review of the medical history~* Have a history of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable (example, due to important side effects or safety risks)~* Have an Eczema Area and Severity Index (EASI) score greater than or equal to (\>=) 16 at screening and at baseline~* Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study~* Must be willing to undergo 4 skin biopsies~* Have an Investigator Global Assessment (IGA) score \>=3 at screening and at baseline~* Have an involved body surface area (BSA) \>=10 percent (%) at screening and at baseline~Exclusion Criteria:~* Has a current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances~* Has ever received any Human interleukin-1 (IL-1) antagonist (example, including but not limited to anakinra, rilonacept)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Bermekimab Dose 1 (Type: EXPERIMENTAL): Participants will receive bermekimab Dose 1 or placebo as an intravenous (IV) infusion weekly from Week 0 to Week 15.
- Part B: Bermekimab Dose 2 (Type: EXPERIMENTAL): Participants will receive bermekimab Dose 2 or placebo as an IV infusion weekly from Week 0 to Week 15.
- Part C: Bermekimab Dose 3 (Type: EXPERIMENTAL): Participants will receive bermekimab or placebo at a higher or lower dose (not less than \[\<\] Dose 1) than Part B, but with a maximum dose of Dose 3 IV weekly based on pharmacokinetic (PK), pharmacodynamic (PD), efficacy, and safety analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).